Becton, Dickinson and Company $BDX Holdings Lifted by TD Waterhouse Canada Inc.

Key Points

• TD Waterhouse Canada increased its Becton, Dickinson and Company stake by 35.2% in the third quarter, bringing its holdings to 130,042 shares valued at approximately $23.3 million. Institutional investors and hedge funds collectively own 86.97% of BDX.
• BDX reported quarterly EPS of $3.23, exceeding estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company issued fiscal 2026 EPS guidance of $12.62–$12.72.
• Analysts maintain a consensus “Hold” rating, with seven Buy, nine Hold, and one Sell recommendation and an average price target of $185.07. Shares recently opened at $191.34, near their 12-month high of $195.99.

TD Waterhouse Canada Inc. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 35.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,042 shares of the medical instruments supplier's stock after acquiring an additional 33,831 shares during the period. TD Waterhouse Canada Inc.'s holdings in Becton, Dickinson and Company were worth $23,278,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. ARS Wealth Advisors Group LLC lifted its position in Becton, Dickinson and Company by 2.9% in the 3rd quarter. ARS Wealth Advisors Group LLC now owns 30,255 shares of the medical instruments supplier's stock valued at $5,416,000 after acquiring an additional 852 shares in the last quarter. Rise Advisors LLC bought a new position in Becton, Dickinson and Company during the 3rd quarter worth about $51,000. Pension & Wealth Management Advisors Inc. increased its holdings in Becton, Dickinson and Company by 12.3% during the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier's stock worth $94,000 after purchasing an additional 56 shares in the last quarter. Howard Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 15.0% in the 3rd quarter. Howard Capital Management LLC now owns 1,954 shares of the medical instruments supplier's stock valued at $350,000 after purchasing an additional 255 shares during the period. Finally, Chemistry Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 13.3% in the 3rd quarter. Chemistry Wealth Management LLC now owns 23,612 shares of the medical instruments supplier's stock valued at $4,227,000 after purchasing an additional 2,769 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,906 shares of company stock worth $1,265,855 in the last quarter. Corporate insiders own 0.40% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Piper Sandler lifted their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. UBS Group started coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a "buy" rating and a $190.00 target price on the stock. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. Finally, Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $185.07.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $191.34 on Friday. The stock has a market capitalization of $52.72 billion, a price-to-earnings ratio of 57.63, a PEG ratio of 12.93 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $195.99. The firm has a fifty day simple moving average of $184.03 and a 200 day simple moving average of $163.70. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the business earned $3.68 EPS. The company's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.